JP2013520466A5 - - Google Patents

Download PDF

Info

Publication number
JP2013520466A5
JP2013520466A5 JP2012554332A JP2012554332A JP2013520466A5 JP 2013520466 A5 JP2013520466 A5 JP 2013520466A5 JP 2012554332 A JP2012554332 A JP 2012554332A JP 2012554332 A JP2012554332 A JP 2012554332A JP 2013520466 A5 JP2013520466 A5 JP 2013520466A5
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
pyrrolidin
pyridin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012554332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520466A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/052662 external-priority patent/WO2011104266A1/en
Publication of JP2013520466A publication Critical patent/JP2013520466A/ja
Publication of JP2013520466A5 publication Critical patent/JP2013520466A5/ja
Pending legal-status Critical Current

Links

JP2012554332A 2010-02-25 2011-02-23 二量体ｉａｐ阻害剤 Pending JP2013520466A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30811410P 2010-02-25 2010-02-25
US61/308,114 2010-02-25
US33392710P 2010-05-12 2010-05-12
US61/333,927 2010-05-12
US38841010P 2010-09-30 2010-09-30
US61/388,410 2010-09-30
PCT/EP2011/052662 WO2011104266A1 (en) 2010-02-25 2011-02-23 Dimeric iap inhibitors

Publications (2)

Publication Number Publication Date
JP2013520466A JP2013520466A (ja) 2013-06-06
JP2013520466A5 true JP2013520466A5 (https=) 2014-03-20

Family

ID=44476672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012554332A Pending JP2013520466A (ja) 2010-02-25 2011-02-23 二量体ｉａｐ阻害剤

Country Status (13)

Country Link
US (1) US8445440B2 (https=)
EP (1) EP2539333A1 (https=)
JP (1) JP2013520466A (https=)
KR (1) KR20130010894A (https=)
CN (1) CN102834389A (https=)
AR (1) AR080253A1 (https=)
BR (1) BR112012021291A2 (https=)
CA (1) CA2790302A1 (https=)
EA (1) EA201201177A1 (https=)
MX (1) MX2012009894A (https=)
TW (1) TW201141846A (https=)
UY (1) UY33236A (https=)
WO (1) WO2011104266A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CA2850330A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
WO2014025759A1 (en) * 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Iap antagonists
TW201428002A (zh) * 2012-11-09 2014-07-16 必治妥美雅史谷比公司 用於抑制細胞凋亡抑制劑之巨環化合物
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2002037626A (ja) 2000-07-27 2002-02-06 Internatl Superconductivity Technology Center ビスマス系高温超電導体の製造方法。
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
KR20060126548A (ko) 2004-02-05 2006-12-07 노파르티스 아게 (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물
CN1926118A (zh) 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007021825A2 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007075525A2 (en) 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0708942A2 (pt) 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
KR20090041391A (ko) 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
CL2007002166A1 (es) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
KR20090082221A (ko) 2006-10-19 2009-07-29 노파르티스 아게 유기 화합물
CN101541325A (zh) * 2006-11-28 2009-09-23 诺瓦提斯公司 Iap抑制剂用于治疗急性髓性白血病的用途
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
KR101149449B1 (ko) 2007-03-20 2012-05-25 삼성전자주식회사 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
JP2010528587A (ja) 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
ES2398791T3 (es) 2008-01-11 2013-03-21 Genentech, Inc. Inhibidores de IAP
EP2242362A4 (en) 2008-01-24 2012-04-11 Tetralogic Pharm Corp IAP INHIBITORS
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2009155709A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
EP2350641B1 (en) 2008-09-22 2014-09-24 Amgen Inc. A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Similar Documents

Publication Publication Date Title
JP2013520466A5 (https=)
US9193719B2 (en) 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
CN101506149B (zh) 脯氨酰羟化酶抑制剂及使用方法
CN102725283B (zh) 作为蛋白激酶抑制剂的化合物和组合物
ES2645947T3 (es) Inhibidores de actividad de quinasa
KR102341064B1 (ko) 리소포스파티드산 수용체 1 (lpar1) 억제제 화합물
JP6473420B2 (ja) 複素環スルホンアミド誘導体及びそれを含有する医薬
US20180057458A1 (en) Lysyl oxidase-like 2 inhibitors and uses thereof
JP2013121919A (ja) 血漿カリクレイン阻害剤
CN112961104A (zh) 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶
JP2010515691A (ja) 第Ｘａ因子阻害剤
JP2019524702A (ja) テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト
JP2015536997A (ja) カンナビノイド受容体媒介性化合物
JP2019519593A (ja) ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
JP2024023490A (ja) 治療用化合物および組成物
US20230212138A1 (en) Phd inhibitor compounds, compositions, and their use
JP2016513726A (ja) がん細胞成長阻害剤としてのテトラヒドロイソキノリン−２−イル−（キナゾリン−４−イル）メタノン化合物
CN103917520A (zh) 苯基胍衍生物
US12404242B2 (en) Compositions and methods for making and using small molecules in the treatment of cancer
KR20260006612A (ko) 이미다졸 함유 화합물, 이의 유도체 및 이의 용도
JP7832179B2 (ja) Ｐｈｄ阻害剤化合物、組成物、及び使用方法
JP2026503167A (ja) Ｇｐｒ３５モジュレーター
TWI912295B (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法